These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24165015)

  • 1. Assessing variation in the costs of care among patients awaiting liver transplantation.
    Axelrod DA; Dzebisashvili N; Lentine K; Segev DL; Dickson R; Tuttle-Newhall E; Freeman R; Schnitzler M
    Am J Transplant; 2014 Jan; 14(1):70-8. PubMed ID: 24165015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs.
    Foxton MR; Al-Freah MA; Portal AJ; Sizer E; Bernal W; Auzinger G; Rela M; Wendon JA; Heaton ND; O'Grady JG; Heneghan MA
    Liver Transpl; 2010 May; 16(5):668-77. PubMed ID: 20440776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease.
    Nadim MK; DiNorcia J; Ji L; Groshen S; Levitsky J; Sung RS; Kim WR; Andreoni K; Mulligan D; Genyk YS
    J Hepatol; 2017 Sep; 67(3):517-525. PubMed ID: 28483678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
    Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
    Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver transplantation cost in the model for end-stage liver disease era: looking beyond the transplant admission.
    Buchanan P; Dzebisashvili N; Lentine KL; Axelrod DA; Schnitzler MA; Salvalaggio PR
    Liver Transpl; 2009 Oct; 15(10):1270-7. PubMed ID: 19790155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of Share 35 on the cost of liver transplantation.
    Berumen J; Misel M; Vodkin I; Halldorson JB; Mekeel KL; Hemming A
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28235131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    Abdallah MA; Kuo YF; Asrani S; Wong RJ; Ahmed A; Kwo P; Terrault N; Kamath PS; Jalan R; Singal AK
    J Hepatol; 2021 Jun; 74(6):1355-1361. PubMed ID: 33326814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes.
    Trotter JF; Osgood MJ
    JAMA; 2004 Apr; 291(15):1871-4. PubMed ID: 15100206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic implications of broader sharing of liver allografts.
    Axelrod DA; Gheorghian A; Schnitzler MA; Dzebisashvili N; Salvalaggio PR; Tuttle-Newhall J; Segev DL; Gentry S; Hohmann S; Merion RM; Lentine KL
    Am J Transplant; 2011 Apr; 11(4):798-807. PubMed ID: 21401867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MELD score in patients awaiting liver transplant: strengths and weaknesses.
    Bernardi M; Gitto S; Biselli M
    J Hepatol; 2011 Jun; 54(6):1297-306. PubMed ID: 21145851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
    Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
    Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
    Kim WR; Mannalithara A; Kwo PY; Bonham CA; Kwong A
    Hepatology; 2023 Mar; 77(3):851-861. PubMed ID: 36052665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCC patients suffer less from geographic differences in organ availability.
    Schuetz C; Dong N; Smoot E; Elias N; Schoenfeld DA; Markmann JF; Yeh H
    Am J Transplant; 2013 Nov; 13(11):2989-95. PubMed ID: 24011291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic impact of MELD on liver transplant centers.
    Axelrod DA; Koffron AJ; Baker T; Al-Saden P; Dixler I; McNatt G; Sumner S; Vaci M; Abecassis M
    Am J Transplant; 2005 Sep; 5(9):2297-301. PubMed ID: 16095512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transplantation after share 35: Impact on pretransplant and posttransplant costs and mortality.
    Nicolas CT; Nyberg SL; Heimbach JK; Watt K; Chen HS; Hathcock MA; Kremers WK
    Liver Transpl; 2017 Jan; 23(1):11-18. PubMed ID: 27658200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective validation of a new priority allocation model for liver transplant candidates: an interim analysis.
    Vitale A; Saracino E; D'Amico FE; Grigoletto F; Burra P; Angeli P; Boccagni P; Brolese A; Zanus G; Neri D; Gringeri E; D'Amico F; Valmasoni M; Carraro A; Gambato M; Feltracco P; Romano A; Buggio M; D'Amico DF; Cillo U
    Transplant Proc; 2009 May; 41(4):1092-5. PubMed ID: 19460489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should All Status 1A Patients Be Prioritized Over High MELD Patients? Concept of Risk Stratification in Extremely Ill Liver Transplant Recipients.
    Safwan M; Nwagu U; Collins K; Abouljoud M; Nagai S
    Transplantation; 2019 Oct; 103(10):2121-2129. PubMed ID: 30747840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.